 Chemotherapy, Adjuvant
"Chemotherapy, Adjuvant" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.
| Descriptor ID |
D017024
|
| MeSH Number(s) |
E02.186.170 E02.319.170
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Chemotherapy, Adjuvant".
Below are MeSH descriptors whose meaning is more specific than "Chemotherapy, Adjuvant".
This graph shows the total number of publications written about "Chemotherapy, Adjuvant" by people in this website by year, and whether "Chemotherapy, Adjuvant" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1992 | 0 | 3 | 3 | | 1993 | 0 | 4 | 4 | | 1994 | 0 | 1 | 1 | | 1995 | 0 | 1 | 1 | | 1996 | 0 | 3 | 3 | | 1997 | 0 | 1 | 1 | | 1998 | 0 | 4 | 4 | | 1999 | 0 | 2 | 2 | | 2000 | 0 | 4 | 4 | | 2001 | 0 | 2 | 2 | | 2002 | 0 | 2 | 2 | | 2003 | 1 | 3 | 4 | | 2004 | 0 | 3 | 3 | | 2005 | 1 | 5 | 6 | | 2006 | 1 | 3 | 4 | | 2007 | 0 | 6 | 6 | | 2008 | 1 | 6 | 7 | | 2009 | 0 | 7 | 7 | | 2010 | 0 | 10 | 10 | | 2011 | 1 | 5 | 6 | | 2012 | 0 | 2 | 2 | | 2013 | 0 | 8 | 8 | | 2014 | 0 | 9 | 9 | | 2015 | 0 | 7 | 7 | | 2016 | 0 | 10 | 10 | | 2017 | 1 | 11 | 12 | | 2018 | 0 | 14 | 14 | | 2019 | 0 | 3 | 3 | | 2020 | 2 | 4 | 6 | | 2021 | 2 | 6 | 8 | | 2022 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Chemotherapy, Adjuvant" by people in Profiles.
-
Nasioudis D, Mastroyannis SA, Ko EM, Haggerty AF, Cory L, Giuntoli RL, Kim SH, Morgan MA, Latif NA. Delay in adjuvant chemotherapy administration for patients with FIGO stage I epithelial ovarian carcinoma is associated with worse survival; an analysis of the National Cancer Database. Gynecol Oncol. 2022 Aug; 166(2):263-268.
-
Furukawa T, Takamatsu M, Inoue Y, Okamoto T, Mie T, Yamada Y, Takeda T, Kasuga A, Matsuyama M, Sasaki T, Ozaka M, Oba A, Ito H, Ono Y, Sato T, Takahashi YU, Saiura A, Sasahira N. Impact of Histological Features on Adjuvant Chemotherapy for Invasive Intraductal Papillary Mucinous Carcinoma. Anticancer Res. 2022 May; 42(5):2645-2655.
-
Baxter NN, Kennedy EB, Bergsland E, Berlin J, George TJ, Gill S, Gold PJ, Hantel A, Jones L, Lieu C, Mahmoud N, Morris AM, Ruiz-Garcia E, You YN, Meyerhardt JA. Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update. J Clin Oncol. 2022 03 10; 40(8):892-910.
-
O'Sullivan CC, Ballman KV, McCall L, Kommalapati A, Zemla T, Weiss A, Mitchell M, Blinder V, Tung NM, Irvin WJ, Lee M, Goetz MP, Symmans WF, Borges VF, Krop I, Carey LA, Partridge AH. Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer. Future Oncol. 2021 Dec; 17(34):4665-4676.
-
Zhou M, Thompson TD, Lin HY, Chen VW, Karlitz JJ, Fontham ETH, Theall KP, Zhang L, Hsieh MC, Pollack LA, Wu XC. Impact of Relative Dose Intensity of FOLFOX Adjuvant Chemotherapy on Risk of Death Among Stage III Colon Cancer Patients. Clin Colorectal Cancer. 2022 06; 21(2):e62-e75.
-
Sukumar JS, Quiroga D, Kassem M, Grimm M, Shinde NV, Appiah L, Palettas M, Stephens J, Gatti-Mays ME, Pariser A, Cherian M, Stover DG, Williams N, Van Deusen J, Wesolowski R, Lustberg M, Ramaswamy B, Sardesai S. Patient preferences and adherence to adjuvant GnRH analogs among premenopausal women with hormone receptor positive breast cancer. Breast Cancer Res Treat. 2021 Nov; 190(2):183-188.
-
Onishi N, Li W, Newitt DC, Harnish RJ, Strand F, Nguyen AA, Arasu VA, Gibbs J, Jones EF, Wilmes LJ, Kornak J, Joe BN, Price ER, Ojeda-Fournier H, Eghtedari M, Zamora KW, Woodard S, Umphrey HR, Nelson MT, Church AL, Bolan PJ, Kuritza T, Ward K, Morley K, Wolverton D, Fountain K, Lopez Paniagua D, Hardesty L, Brandt KR, McDonald ES, Rosen M, Kontos D, Abe H, Sheth D, Crane E, Dillis C, Sheth P, Hovanessian-Larsen L, Bang DH, Porter B, Oh KY, Jafarian N, Tudorica LA, Niell B, Drukteinis J, Newell MS, Giurescu ME, Berman E, Lehman CD, Partridge SC, Fitzpatrick KA, Borders MH, Yang WT, Dogan B, Goudreau SH, Chenevert T, Yau C, DeMichele A, Berry DA, Esserman LJ, Hylton NM. Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response. Radiology. 2021 11; 301(2):295-308.
-
Partridge AH, Niman SM, Ruggeri M, Peccatori FA, Azim HA, Colleoni M, Saura C, Shimizu C, Sætersdal AB, Kroep JR, Mailliez A, Warner E, Borges VF, Amant F, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Walshe JM, Borrego MR, Moore HC, Saunders C, Cardoso F, Susnjar S, Bjelic-Radisic V, Smith KL, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Pagani O. Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy. Breast. 2021 Oct; 59:327-338.
-
Zhou YW, Long YX, Song K, Liang LB, Cheng K, Chen Y, Liu JY. Anterior wall adenocarcinoma of bladder with similar clinicopathological and prognostic characteristics as common bladder carcinomas should not be treated as or classified into urachal adenocarcinomas. Cancer Med. 2021 08; 10(16):5415-5428.
-
Eom KY, van Londen GJ, Li J, Dahman B, Bradley C, Sabik LM. Changes in initiation of adjuvant endocrine therapy for breast cancer after state health reform. BMC Cancer. 2021 May 01; 21(1):487.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|